TY - JOUR
T1 - Intravenous etidronate in the management of malignant hypercalcemia
AU - Ryzen, E.
AU - Martodam, R. R.
AU - Troxell, M.
AU - Benson, A.
AU - Paterson, A.
AU - Shepard, K.
AU - Hicks, R.
PY - 1985/5/29
Y1 - 1985/5/29
N2 - The treatment of hypercalcemia remains a common problem in the management of many patients with cancer. We have used intravenously administered etidronate disodium as a therapy for hypercalcemia in 26 patients with malignant disease. Patients with persistent hypercalcemia despite adequate hydration and a serum creatinine level less than or equal to 1.5 mg/dL were allowed on study. Treatment consisted of intravenously administered etidronate disodium at 7.5 mg/kg/day in 250 mL of saline infused over two hours on 1, 2, 3, or 4 consecutive days. The serum calcium level in 19 (73%) of 26 patients returned to the normal range with a mean response time of 3 ± 2 days. Similar response rates were seen in patients with a variety of tumors, including breast cancer, non-small-cell lung cancer, and multiple myeloma. Intravenously administered etidronate appears to be safe and effective therapy for hypercalcemia in patients with malignant disease.
AB - The treatment of hypercalcemia remains a common problem in the management of many patients with cancer. We have used intravenously administered etidronate disodium as a therapy for hypercalcemia in 26 patients with malignant disease. Patients with persistent hypercalcemia despite adequate hydration and a serum creatinine level less than or equal to 1.5 mg/dL were allowed on study. Treatment consisted of intravenously administered etidronate disodium at 7.5 mg/kg/day in 250 mL of saline infused over two hours on 1, 2, 3, or 4 consecutive days. The serum calcium level in 19 (73%) of 26 patients returned to the normal range with a mean response time of 3 ± 2 days. Similar response rates were seen in patients with a variety of tumors, including breast cancer, non-small-cell lung cancer, and multiple myeloma. Intravenously administered etidronate appears to be safe and effective therapy for hypercalcemia in patients with malignant disease.
UR - http://www.scopus.com/inward/record.url?scp=0021928106&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021928106&partnerID=8YFLogxK
U2 - 10.1001/archinte.145.3.449
DO - 10.1001/archinte.145.3.449
M3 - Article
C2 - 3919667
SN - 0003-9926
VL - 145
SP - 449
EP - 452
JO - Archives of Internal Medicine
JF - Archives of Internal Medicine
IS - 3
ER -